Alcaraz Maria José, Payá Miguel
University of Valencia, Department of Pharmacology, Av Vicent Andres Estelles s/n, 46100 Burjasot, Valencia, Spain.
Curr Opin Investig Drugs. 2006 Nov;7(11):974-9.
Marine organisms are a rich source of bioactive metabolites. A number of potential anti-inflammatory compounds have been isolated from marine invertebrates that exhibit phospholipase A2 inhibitory activity. A wide range of marine compounds have been investigated for their anti-inflammatory properties. Cacospongionolide B and petrosaspongiolide M are representative examples of anti-inflammatory compounds in experimental models of acute or chronic inflammation. The mechanisms of action of these compounds include phospholipase A, inhibition as well as the control of nuclear factor-B activation and inflammatory gene expression. Although many marine compounds exhibit interesting anti-inflammatory properties, few have entered clinical trials. The future development of this class of compounds as anti-inflammatory drugs requires the introduction of novel molecular targets of therapeutic relevance in addition to biotechnological approaches for the production of these molecules.
海洋生物是生物活性代谢物的丰富来源。已从具有磷脂酶A2抑制活性的海洋无脊椎动物中分离出多种潜在的抗炎化合物。人们对多种海洋化合物的抗炎特性进行了研究。在急慢性炎症的实验模型中,海绵硬脂内酯B和岩海绵内酯M是抗炎化合物的代表性实例。这些化合物的作用机制包括抑制磷脂酶A以及控制核因子-κB的激活和炎症基因表达。尽管许多海洋化合物具有有趣的抗炎特性,但很少有进入临床试验的。这类化合物作为抗炎药物的未来发展,除了生产这些分子的生物技术方法外,还需要引入具有治疗相关性的新型分子靶点。